Video Upload Options

References

1. Allen CE, Parsons DW. Biological and clinical significance of somaticmutations in Langerhans cell histiocytosis and related histiocytic neoplasticdisorders. Hematology Am Soc Hematol Educ Program. 2015;2015:559-64. doi:10.1182/asheducation-2015.1.559. Review.
2. Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y. The RAS/MAPK syndromes:novel roles of the RAS pathway in human genetic disorders. Hum Mutat. 2008Aug;29(8):992-1006. doi: 10.1002/humu.20748. Review.
3. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, CalicchioML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M,Fleming MD, Rollins BJ. Recurrent BRAF mutations in Langerhans cellhistiocytosis. Blood. 2010 Sep 16;116(11):1919-23. doi:10.1182/blood-2010-04-279083. Epub 2010 Jun 2.
4. Bosco J, Allende A, Varikatt W, Lee R, Stewart GJ. Does the BRAF(V600E)mutation herald a new treatment era for Erdheim-Chester disease? A case-basedreview of a rare and difficult to diagnose disorder. Intern Med J. 2015Mar;45(3):348-51. doi: 10.1111/imj.12685. Review.
5. Campochiaro C, Tomelleri A, Cavalli G, Berti A, Dagna L. Erdheim-Chesterdisease. Eur J Intern Med. 2015 May;26(4):223-9. doi: 10.1016/j.ejim.2015.03.004.Epub 2015 Apr 10. Review.
6. Cives M, Simone V, Rizzo FM, Dicuonzo F, Cristallo Lacalamita M, Ingravallo G,Silvestris F, Dammacco F. Erdheim-Chester disease: a systematic review. Crit Rev Oncol Hematol. 2015 Jul;95(1):1-11. doi: 10.1016/j.critrevonc.2015.02.004. Epub2015 Feb 17. Review.
7. Dhomen N, Marais R. New insight into BRAF mutations in cancer. Curr Opin GenetDev. 2007 Feb;17(1):31-9. Review.
8. Gelb BD, Tartaglia M. Noonan Syndrome with Multiple Lentigines. 2007 Nov 30[updated 2015 May 14]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): Universityof Washington, Seattle; 1993-2020. Available fromhttp://www.ncbi.nlm.nih.gov/books/NBK1383/
9. Harmon CM, Brown N. Langerhans Cell Histiocytosis: A Clinicopathologic Review and Molecular Pathogenetic Update. Arch Pathol Lab Med. 2015 Oct;139(10):1211-4. doi: 10.5858/arpa.2015-0199-RA. Review.
10. Haroche J, Arnaud L, Cohen-Aubart F, Hervier B, Charlotte F, Emile JF, Amoura Z. Erdheim-Chester disease. Curr Rheumatol Rep. 2014 Apr;16(4):412. doi:10.1007/s11926-014-0412-0. Review.
11. Rauen KA. Cardiofaciocutaneous Syndrome. 2007 Jan 18 [updated 2016 Mar 3]. In:Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A,editors. GeneReviews® [Internet]. Seattle (WA): University of Washington,Seattle; 1993-2020. Available from http://www.ncbi.nlm.nih.gov/books/NBK1186/
12. Roden AC, Hu X, Kip S, Parrilla Castellar ER, Rumilla KM, Vrana JA, VassalloR, Ryu JH, Yi ES. BRAF V600E expression in Langerhans cell histiocytosis:clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonarycases. Am J Surg Pathol. 2014 Apr;38(4):548-51. doi:10.1097/PAS.0000000000000129.
13. Rollins BJ. Genomic Alterations in Langerhans Cell Histiocytosis. HematolOncol Clin North Am. 2015 Oct;29(5):839-51. doi: 10.1016/j.hoc.2015.06.004.Review.
14. Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, Roberts AE, Robinson W, Takemoto CM, Noonan JA. Noonan syndrome: clinical features,diagnosis, and management guidelines. Pediatrics. 2010 Oct;126(4):746-59. doi:10.1542/peds.2009-3207. Epub 2010 Sep 27. Review.
15. Salgado CM, Basu D, Nikiforova M, Bauer BS, Johnson D, Rundell V, GrunwaldtLJ, Reyes-Múgica M. BRAF mutations are also associated with neurocutaneousmelanocytosis and large/giant congenital melanocytic nevi. Pediatr Dev Pathol.2015 Jan-Feb;18(1):1-9. doi: 10.2350/14-10-1566-OA.1. Epub 2014 Dec 9.
16. Sarkozy A, Carta C, Moretti S, Zampino G, Digilio MC, Pantaleoni F, Scioletti AP, Esposito G, Cordeddu V, Lepri F, Petrangeli V, Dentici ML, Mancini GM,Selicorni A, Rossi C, Mazzanti L, Marino B, Ferrero GB, Silengo MC, Memo L,Stanzial F, Faravelli F, Stuppia L, Puxeddu E, Gelb BD, Dallapiccola B, TartagliaM. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneoussyndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat.2009 Apr;30(4):695-702. doi: 10.1002/humu.20955.
17. Satoh T, Smith A, Sarde A, Lu HC, Mian S, Trouillet C, Mufti G, Emile JF,Fraternali F, Donadieu J, Geissmann F. B-RAF mutant alleles associated withLangerhans cell histiocytosis, a granulomatous pediatric disease. PLoS One.2012;7(4):e33891. doi: 10.1371/journal.pone.0033891. Epub 2012 Apr 10. Erratumin: PLoS One. 2012;7(6).doi:10.1371/annotation/74a67f4e-a536-4b3f-a350-9a4c1e6bebbd. Mian, Sophie[corrected to Mian, Syed].
18. Zebary A, Omholt K, van Doorn R, Ghiorzo P, Harbst K, Hertzman Johansson C,Höiom V, Jönsson G, Pjanova D, Puig S, Scarra GB, Harland M, Olsson H, EgyhaziBrage S, Palmer J, Kanter-Lewensohn L, Vassilaki I, Hayward NK, Newton-Bishop J, Gruis NA, Hansson J; Melanoma Genetics Consortium (GenoMEL). Somatic BRAF andNRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMELstudy. J Invest Dermatol. 2014 Jan;134(1):287-290. doi: 10.1038/jid.2013.270.Epub 2013 Jun 14.